Yellow fever vaccine: a successful vaccination of an immunocompromised patient.
We report on the successful vaccination of a patient, 21/2 yr after bone marrow transplantation for myeloma. He was not severely immunosupressed and responded to the yellow fever vaccine (17D, a live attenuated vaccine) without any adverse affects.
Gowda
R
R
Department of Infection and Tropical Medicine, Sheffield Virology Services, Royal Hallamshire Hospital, Sheffield, UK. ravigowda1@yahoo.com
Cartwright
K
K
Bremner
J A G
JA
Green
S T
ST
D000914:Antibodies, Viral / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D006801:Humans; D016867:Immunocompromised Host; D007630:Kenya; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D014195:Travel; D014613:Vaccines, Attenuated / Q000276:immunology; D022341:Yellow Fever Vaccine / Q000276:immunology*; D015005:Yellow fever virus / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D022341:Yellow Fever Vaccine